ZLAB · Zai Lab Ltd
$26.01
-0.01 (-0.04%)
At close · Aug 21
View the 10-Q filed Aug 6, 2026
Customer concentration
— top customer 18% of receivables
One customer — 18% of receivables (As of June 30, 2026)
“As of June 30, 2026, our largest customer accounted for approximately 18% of our total accounts receivable collectively.”
Market Cap
$2.92B
Shares
112.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.01
Open$26.25
Day$25.72–26.29
52W close$16.30–35.04
Avg vol 30d1.1M
Short int6.5M · 5.8% float · 10.9d
Short vol75%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+27%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
52%
mid-range
Momentum
relative strength
1-month return
+35%
trailing
6-month return
+41%
trailing
YTD return
+47%
this year
Relative strength
+30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $20 › 200d $20 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$669.9K over 90 days · 100% sells
Short interest
Rising
5.82% of float · ▲ +2.9% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
93 holders — near 3-yr low, contrarian setup
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
Gross margin
0%
EPS growth
+38%
Y/Y
Free cash flow
$-158.9M
Balance sheet
$475.0M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2024
VYVGART annual sales in China
· annual
at least $1B
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total revenue
· full year 2025
at least $460M
Guided vs delivered
· last 1 settled
Total revenue
full year 2025
guided at least $460M
$460.16M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+27%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Golden cross
50d $20 › 200d $20 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +16 funds added
Insider flow
Distributing
Net -$669.9K over 90 days · 100% sells
Short interest
Rising
5.82% of float · ▲ +2.9% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
93 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $16
Now $26 · 52%
Range high $35
vs 200-day avg +32%
vs 50-day avg +27%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Product revenue, net (At CER) non-GAAP | -10% | Six Months Ended June 30 | — |
|
|
|||
| Adjusted loss from operations non-GAAP | -$51.92M | Three Months Ended March 31 | — |
GAAP → non-GAAP reconciliationGAAP Loss from operations -69.39M
+3.94M Depreciation and amortization expenses
+13.52M Share-based compensation
= Adjusted loss from operations -51.92M
|
|||
| Product revenue, net non-GAAP | 15% | Full-year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZLAB
this stock
Zai Lab Ltd
|
$2.92B | +47.4% | +15.3% | — | 5.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZLAB | +0.4% | +35.3% | +41.2% | +42.4% | +47.5% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +1.8% | +31.7% | +29.7% | +39.9% | +35.2% |
Key facts
CIK
1704292
CUSIP
98887Q104
13F (30d)
98 filings
86 filers
Visit website
Investor relations